Concerning Biosimilar product, are Low-molecular-weight heparins (LMWHs) considered in the update of LPTh art 13 like in EU or with a reduced documentation?

No, LMWHs are still considered pharmaceutical products with new active substances and not biosimilars or pharmaceutical products with known active substances.